BRCA1 and pancreatic adenocarcinoma: Actionable BRCA1/2 mutations detected by NGS were not limited to breast and ovarian cancer, but were observed in several tumor types (e.g. colorectal cancer, glioblastoma, head and neck cancer, pancreatic adenocarcinoma, prostate cancer).